New adipocytokines (vaspin, apelin, visfatin, adiponectin) levels in children treated with valproic acid

European Cytokine Network

Volumn 22, Issue 2, 2011, Pages 118-122

  Meral, Cihan ^a   Cekmez, Ferhat ^a   Vurucu, Sebahattin ^a   Tascilar, Emre ^a   Pirgon, Ozgur ^a   Canpolat, F Emre ^a   Ipcioglu, Osman Metin ^a   Aydemir, Gokhan ^a   Aydinoz, Secil ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Adiponectin; Apelin; Valproate; Vaspin; Visfatin

Indexed keywords

ADIPOCYTOKINE; APELIN; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL; VALPROIC ACID; VASPIN;

AGE; ANTICONVULSANT THERAPY; ARTICLE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; EPILEPSY; FEMALE; GENERALIZED EPILEPSY; GLUCOSE METABOLISM; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; OBESITY; PRESCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOKINES; ADIPONECTIN; ADOLESCENT; ANTICONVULSANTS; CHILD; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SERPINS; VALPROIC ACID; WEIGHT GAIN;

EID: 79960983940     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2011.0284     Document Type: Article

References (35)

1. Isojarvi JL, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579-84.
2. Easter D, O'Bryan-Tear CG, Verity C.Weight gain with valproate or carbamazepine-A reappraisal. Seizure 1997; 6: 121-5.
3. Verrotti A, la Torre R, Trotta D, Mohn A, Chiarelli F. Valproateinduced insulin resistance and obesity in children. Horm Res 2009; 71: 125-31.
4. Corman C, Leung N, Guberman A. Weight gain in epileptic patient during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997; 24: 240-4.
5. Grosso S, Mostardini R, Piccini B, Balestri P. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann Pharmacother 2009 Jan; 43: 45-50.
6. Luef G, Abraham I, Hoppichler F, et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 2002; 51: 1274-8.
7. Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojarvi JI. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002; 43: 514-7.
8. Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999; 53: 230-2.
9. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
10. Lihn, A.S., Pedersen, S.B., Richelsen, B. Adiponectin: action, regulation and association to insulin sensitivity. Obesity Reviews 2005; 6: 13-21.
11. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hypersulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.
12. Punthakee Z, Delvin EE, O'Loughlin, J, et al. Adiponectin, adiposity and insulin resistance in children and adolescents. J Clin Endocrinol Metab 2006; 91: 2119-25.
13. Gil-Campos M, Canete R, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clinical Nutrition 2004; 23: 963-74.
14. Hosoya M, Kawamata Y, Fukusumi S, et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000; 275: 21061-7.
15. Klöting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339: 430-6.
16. Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372-7.
17. Cole TJ, BellizziMC, FlegalKM, DietzWH. Establishing a standard definition for child overweight and obesity worldwide: international survey. Br Med J 2000; 320: 1240-3.
18. Guzzaloni G, Grugni G, Mazzilli G, Moro D, Morabito F. Comparison between beta-cell function and insulin resistance indexes in prepubertal and pubertal obese children. Metabolism 2002; 51: 1011-6.
19. Vaccaro O, Masulli M, Cuomo V, et al. Comparative evaluation of simple indices of insulin resistance. Metabolism 2004; 53: 1522-6.
20. Atabek ME, Pirgon O. Assessment of insulin sensitivity from measurements in fasting state and during an oral glucose tolerance test in obese children. J Pediatr Endocrinol Metab 2007; 20: 187-95.
21. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in men. Diabetologia 1985; 28: 412-9.
22. Keskin M, Kurtoglu S, Kendirci M, et al. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005; 115: 500-3.
23. Rajala MW, Scherer PE. Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 3765-73.
24. Peterson MC. Circulating transforming growth factor beta-1: a partial molecular explanation for associations between hypertension, diabetes, obesity, smoking and human disease involving fi brosis. Med Sci Monit 2005; 11: RA229-32.
25. Kralisch S, Bluher M, Paschke R, et al. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem 2007; 7: 39-45.
26. Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-6.
27. Hammarstedt A, Pihlajamaki J, Sopasakis VR, et al. Visfatin is an adipokine but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006; 91: 1181-4.
28. Rauchenzauner M, Haberlandt E, Scholl-Bürgi S, et al. Adiponectin and visfatin concentrations in children treated with valproic acid. Epilepsia 2008; 49: 353-7.
29. Qiao L, Schaack J, Shao J. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 2006; 147: 865-74.
30. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identifi ed adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764-71.
31. Habata Y, Fujii R, Hosoya M, et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta 1999; 1452: 25-35.
32. O'Carroll AM, Selby TL, Palkovits M, Lolait SJ. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta 2000; 1492: 72-80.
33. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 2004; 118: 119-25.
34. Hida K, Wada J, Eguchi H, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005; 102: 10610-5.
35. Atabek ME, Pirgon O, Kurtoglu S. Assessment of abnormal glucose homeostasis and insulin resistance in Turkish obese children and adolescents. Diabetes Obes Metab 2007; 9: 304-10.